This article is more than 5 years old. Information may no longer be current.
FDA approves Sun Pharma’s dry eye treatment
Click Here to Manage Email Alerts
The FDA has approved Cequa for the treatment of dry eye disease, Sun Pharmaceutical Industries announced in a press release.
Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production, the release said.
“Dry eye disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated,” Abhay Gandhi, Sun Pharma North America CEO, said in the release. “The U.S. FDA approval of Cequa represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun’s Ophthalmics business. Cequa, with its novel nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear solution form.”